Protocol Ledger

NCT03487107 · Phase III · COMPLETED

Phase 3 Study of Yimitasvir Phosphate Capsules

Interventional Phase III clinical trial protocol NCT03487107 sponsored by Sunshine Lake Pharma Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-17 Enrollment: 362 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03487107
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)362 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03487107
Protocol FieldVerified Registry Value
NCT IdentifierNCT03487107
Consolidated Lead SponsorSunshine Lake Pharma Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment362 participants (ACTUAL)
Registered Start Date2018-04-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI